<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04660266</url>
  </required_header>
  <id_info>
    <org_study_id>0696-20-RMB</org_study_id>
    <nct_id>NCT04660266</nct_id>
  </id_info>
  <brief_title>Accuracy of Ultrasound Exam, Including Doppler and Elastography, in the Diagnosis of VOD, Following Bone Marrow Transplantation</brief_title>
  <official_title>Accuracy of Ultrasound Exam, Including Doppler and Elastography, in the Diagnosis of VOD, in the 21 Days Following Bone Marrow Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study:&#xD;
&#xD;
      Validation of the use of intentional ultrasound examination, which includes Doppler and&#xD;
      elastography for the diagnosis of obstructive venous disease of the liver within 21 days&#xD;
      after bone marrow transplantation.&#xD;
&#xD;
      Protocol:&#xD;
&#xD;
      Patients who are planned for a bone marrow transplantaion will be recruited for the study by&#xD;
      the staff of the Transplant Department. Inclusion criteria: Patients over the age of 18&#xD;
      before a bone marrow transplantation.&#xD;
&#xD;
      Eligibility criteria: Transplanted under 18 years of age&#xD;
&#xD;
      Research protocol:&#xD;
&#xD;
      After informed consent, patients will undergo an ultrasound examination before the&#xD;
      transplant.&#xD;
&#xD;
      After 14 days and again after 21 days patients will undergo two more US exams, If there is a&#xD;
      change in their clinical condition the patients will undergo additional examination&#xD;
      accordingly.&#xD;
&#xD;
      At the same time on the 14th and 21st day a clinical evaluation will be performed by the&#xD;
      clinical physician in the transplant department based on clinical criteria of European Blood&#xD;
      and Brain Transplant Association (EBMT).&#xD;
&#xD;
      The results of the clinical evaluation and blood test results will be collected.&#xD;
&#xD;
      Patients will be divided into two groups:&#xD;
&#xD;
        -  Control group: Patients who did not develop VOD( veno occlusive disease ) during 21&#xD;
           days.&#xD;
&#xD;
        -  Study group: Patients who developed VOD during 21 days.&#xD;
&#xD;
      All ultrasound examination data will be compared between the two groups in&#xD;
&#xD;
      In addition will be collected:&#xD;
&#xD;
        -  Demographics - age, sex.&#xD;
&#xD;
        -  Background diseases including heart and liver diseases.&#xD;
&#xD;
        -  Basic disease as a transplantation cause.&#xD;
&#xD;
      All data will be collected anonymously and coded separately.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study:&#xD;
&#xD;
      Validation of the use of intentional ultrasound examination, which includes Doppler and&#xD;
      elastography for the diagnosis of obstructive venous disease of the liver within 21 days&#xD;
      after bone marrow transplantation.&#xD;
&#xD;
      Protocol:&#xD;
&#xD;
      Patients who are planned for a bone marrow transplantaion will be recruited for the study by&#xD;
      the staff of the Transplant Department. Inclusion criteria: Patients over the age of 18&#xD;
      before a bone marrow transplantation.&#xD;
&#xD;
      Eligibility criteria: Transplanted under 18 years of age&#xD;
&#xD;
      Research protocol:&#xD;
&#xD;
      After informed consent, patients will undergo an ultrasound examination before the&#xD;
      transplant.&#xD;
&#xD;
      The test will include:&#xD;
&#xD;
        1. Demonstration of liver including its size.&#xD;
&#xD;
        2. Gallbladder demonstration including its width and wall thickness.&#xD;
&#xD;
        3. Main portal vein width, Speed and flow direction in main portal vein.&#xD;
&#xD;
        4. Evaluation of umbilical vein in the falciform ligament to check existence of flow and&#xD;
           venous width in case it opened.&#xD;
&#xD;
        5. Assessment of existence a small / medium or large amount of ascites measurement of&#xD;
           resistance index in the main hepatic artery.&#xD;
&#xD;
        6. Complete elastography examination.&#xD;
&#xD;
      After 14 days and again after 21 days patients will undergo two more US exams, If there is a&#xD;
      change in their clinical condition the patients will undergo additional examination&#xD;
      accordingly.&#xD;
&#xD;
      At the same time on the 14th and 21st day a clinical evaluation will be performed by the&#xD;
      clinical physician in the transplant department based on clinical criteria of European Blood&#xD;
      and Brain Transplant Association (EBMT).&#xD;
&#xD;
      The results of the clinical evaluation and blood test results will be collected.&#xD;
&#xD;
      Patients will be divided into two groups:&#xD;
&#xD;
        -  Control group: Patients who did not develop VOD( veno occlusive disease ) during 21&#xD;
           days.&#xD;
&#xD;
        -  Study group: Patients who developed VOD during 21 days.&#xD;
&#xD;
      All ultrasound examination data will be compared between the two groups in&#xD;
&#xD;
      In addition will be collected:&#xD;
&#xD;
        -  Demographics - age, sex.&#xD;
&#xD;
        -  Background diseases including heart and liver diseases.&#xD;
&#xD;
        -  Basic disease as a transplantation cause.&#xD;
&#xD;
      All data will be collected anonymously and coded separately.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>liver evaluation by US before, 14 days and 21 days after bone marrow transplantation, in the purpose to predict the appearance of Veno occlusive disease.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of liver ultrasound in predicting VOD</measure>
    <time_frame>21 days</time_frame>
    <description>ultrasound results inculding gray scale , doppler and elastography will be compared to the clinical diagnosis of VOD the diagnosis of VOD will be performed according to the Europian Society for Blood and Marrow transplantation revised criteria&#xD;
presence of ascites yes/no&#xD;
liver enlagement more than 17 cm&#xD;
Bilirubin &gt;2 mg/dl</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>VOD</condition>
  <condition>Ultrasound Therapy; Complications</condition>
  <arm_group>
    <arm_group_label>all cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Liver Ultrasound</intervention_name>
    <description>liver ultrasound examination, including gray-scale and seven Doppler examination</description>
    <arm_group_label>all cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over the age of 18 before a bone marrow transplantation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Transplanted under 18 years of age.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nira Beck Razi, MD</last_name>
    <phone>972502061204</phone>
    <email>n_beck_razi@mbam.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <state>Israek</state>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>NIRA BECK-RAZI, md</last_name>
      <phone>97247772664</phone>
      <email>n_beck_razi@rambam.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/6363247/</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/19766729/</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/17768390/</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/8420443/</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/3321587/</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/27183098/</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.22772</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://europepmc.org/article/med/30895833</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/9240551/</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/29767845/</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://www.x-mol.com/paper/1276245089442099200</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>December 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

